ArticleScientific reports2025
The influence of social capital and evidence-based orientation on psychiatrists' attitudes toward antipsychotic polypharmacy in schizophrenia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite showing no superiority over monotherapy, antipsychotic polypharmacy (APP) is used in up to half of schizophrenia patients. However, no standardized instrument currently exists to systematically evaluate clinicians' attitudes toward APP and the role of social capital, underscoring the need for such a tool. This study presents the development of a scale designed to measure psychiatrists' attitudes toward APP. It further investigates factors associated with more evidence-based medicine (EBM) attitudes, including social capital, general EBM orientation, and demographics. The Knowledge and Attitude scale toward Antipsychotic Polypharmacy in Schizophrenia (KAAPS) was developed and pre-tested. The questionnaire also incorporated measures of professional social capital, the Evidence-Based Practice Attitude Scale (Aaron et al., 2004), and demographic variables. The web-based survey was distributed to 1618 Belgian psychiatrists and psychiatry residents. Psychometric characteristics of the KAAPS were assessed to ensure validity and factors potentially associated with the KAAPS score were tested. Among 152 complete respondents, the mean KAAPS score was 55.8 out of 102 (SD = 13.7), indicating a tendency toward evidence-based knowledge and attitudes. Factors associated with lower evidence-based attitudes included higher professional social capital (β= -0.254, p < 0.01), working in non-multidisciplinary settings (β= -9.1435, p < 0.001), belonging to the Dutch-speaking community (β= -5.133, p = 0.036) and higher APP prescription rates (β= -0.194, p < 0.001). Practicing cognitive behavioural therapy (β = 6.366, p < 0.01) was associated with higher KAAPS scores, whereas intrinsic EBM orientation showed no significant association (β = 0.231, p = 0.083). Applied across diverse populations or countries, the KAAPS scale may help identify clinical circumstances in which antipsychotic polypharmacy is most frequently considered appropriate, thereby informing targeted educational interventions and supporting the evaluation of implementation strategies. Incorporating social network dynamics into these approaches, given the influence of social capital on psychiatrists' attitudes toward antipsychotic polypharmacy, may further contribute to reducing inappropriate prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.